Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition
Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn’s disease. We describe a 41-year-old male with a history of psoriasis who developed new-onset Crohn’s...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1628461/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318207025840128 |
|---|---|
| author | Huiling Dai Chenyi Xu Yehuang Wang Kunlan Wu Yang Zhang Hao Ge Yanlan Wu |
| author_facet | Huiling Dai Chenyi Xu Yehuang Wang Kunlan Wu Yang Zhang Hao Ge Yanlan Wu |
| author_sort | Huiling Dai |
| collection | DOAJ |
| description | Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn’s disease. We describe a 41-year-old male with a history of psoriasis who developed new-onset Crohn’s disease accompanied by a perianal abscess after prolonged secukinumab treatment. The patient experienced increased bowel movements and postoperative fever, and colonoscopy revealed diffuse colonic inflammation and deep ulcerations; histopathology confirmed chronic active enteritis with epithelioid granulomas. Infectious causes and other differential diagnoses were excluded. Treatment with corticosteroids and mesalamine led to symptom resolution and normalization of inflammatory markers. This case illustrates a rare but important adverse effect of IL-17A inhibition and emphasizes the dual role of IL-17A in promoting skin inflammation while maintaining intestinal homeostasis. Careful evaluation of gastrointestinal history and close monitoring during therapy are essential to prevent and manage potential intestinal complications. |
| format | Article |
| id | doaj-art-e0b6fabb7b2a45f59bc9bee21d25d83f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-e0b6fabb7b2a45f59bc9bee21d25d83f2025-08-20T03:50:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16284611628461Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibitionHuiling Dai0Chenyi Xu1Yehuang Wang2Kunlan Wu3Yang Zhang4Hao Ge5Yanlan Wu6Colon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaColon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaColon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaColon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaJiangsu Clinical Innovation Center For Anorectal Diseases of Traditional Chinese Medicine (T.C.M), Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaSchool of Clinical Medicine, Jiangsu Health Vocational College, Nanjing, ChinaColon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaSecukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn’s disease. We describe a 41-year-old male with a history of psoriasis who developed new-onset Crohn’s disease accompanied by a perianal abscess after prolonged secukinumab treatment. The patient experienced increased bowel movements and postoperative fever, and colonoscopy revealed diffuse colonic inflammation and deep ulcerations; histopathology confirmed chronic active enteritis with epithelioid granulomas. Infectious causes and other differential diagnoses were excluded. Treatment with corticosteroids and mesalamine led to symptom resolution and normalization of inflammatory markers. This case illustrates a rare but important adverse effect of IL-17A inhibition and emphasizes the dual role of IL-17A in promoting skin inflammation while maintaining intestinal homeostasis. Careful evaluation of gastrointestinal history and close monitoring during therapy are essential to prevent and manage potential intestinal complications.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1628461/fullpsoriasissecukinumabperianal abscessCrohn’s diseasedrug-related adverse reactions |
| spellingShingle | Huiling Dai Chenyi Xu Yehuang Wang Kunlan Wu Yang Zhang Hao Ge Yanlan Wu Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition Frontiers in Immunology psoriasis secukinumab perianal abscess Crohn’s disease drug-related adverse reactions |
| title | Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition |
| title_full | Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition |
| title_fullStr | Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition |
| title_full_unstemmed | Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition |
| title_short | Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition |
| title_sort | secukinumab induced crohn s disease in a psoriasis patient a case report highlighting paradoxical reactions to il 17 inhibition |
| topic | psoriasis secukinumab perianal abscess Crohn’s disease drug-related adverse reactions |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1628461/full |
| work_keys_str_mv | AT huilingdai secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT chenyixu secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT yehuangwang secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT kunlanwu secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT yangzhang secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT haoge secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition AT yanlanwu secukinumabinducedcrohnsdiseaseinapsoriasispatientacasereporthighlightingparadoxicalreactionstoil17inhibition |